Format

Send to

Choose Destination
Catheter Cardiovasc Interv. 2019 Feb 17. doi: 10.1002/ccd.28129. [Epub ahead of print]

Transfemoral transcatheter aortic valve implantation after aortic valve repair with HAART 300 device.

Author information

1
Department of Cardiovascular Surgery, Sana-Herzzentrum Cottbus, Cottbus, Germany.
2
Department of Cardiology, Sana-Herzzentrum Cottbus, Cottbus, Germany.

Abstract

We report the first successful case, to our knowledge, of CoreValve Evolut R (Medtronic, Minneapolis, MN) implantation into a failed HAART 300 aortic annuloplasty device (BioStable Science & Engineering, TX). An 81-year-old man presented with severe symptomatic aortic regurgitation secondary to failure of the 21 mm HAART 300 device, which had been implanted 45 days previously. Transthoracic echocardiography (TTE) revealed grade 3 aortic regurgitation with central jet, without aortic valve stenosis. Because of the high risk for redo surgery, the heart team proceeded with femoral transcatheter aortic valve implantation. The 26 mm CoreValve Evolut R was deployed into the 21 mm HAART 300 device without difficulty or complications. There were no intraoperative or postoperative complications. The patient was discharged after 5 days. TTE showed a mean aortic valve gradient of 18 mmHg, with minimal paravalvular leak. Our experience suggests that CoreValve Evolut R implantation may be an attractive option in patients with failed HAART 300 aortic annuloplasty.

KEYWORDS:

aortic annuloplasty device; aortic valve plasty; transcatheter aortic valve implantation

PMID:
30773825
DOI:
10.1002/ccd.28129

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center